Breaking News Instant updates and real-time market news.

ESALY

Eisai

$0.00

(0.00%)

, BIIB

Biogen

$226.71

-93.76 (-29.26%)

05:24
03/22/19
03/22
05:24
03/22/19
05:24

Eisai announces initiation of Phase III BAN2401 study in Alzheimer's disease

Eisai (ESALY) announced that a global Phase III clinical study of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer's disease has been initiated. BAN2401 is being jointly developed by Eisai and Biogen (BIIB). The "Clarity AD" is a global placebo-controlled, double-blind, parallel-group, randomized study in 1,566 patients with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia with confirmed amyloid pathology in the brain. "After discussion with regulatory agencies based on the results of a Phase II clinical study, a single Phase III clinical study is being initiated to support a filing for BAN2401," Eisai said in a statement. The treatment group will be administered a dosage of 10 mg/kg bi-weekly of BAN2401, with patients allocated in a 1:1 ratio to receive either placebo or the treatment group. The primary endpoint is the change from baseline in the Clinical Dementia Rating-Sum of Boxes at 18 months of treatment. Respective changes from baseline to 18 months of treatment in the AD composite score, AD Assessment Scale-Cognitive Subscale, and brain amyloid levels as measured by amyloid positron emission tomography have been set as key secondary endpoints, the company said. It added, " Eisai aims to create innovative medicines for Alzheimer's disease as soon as possible in order to further contribute to addressing the unmet medical needs of, as well as potentially increasing the benefits provided to, patients and their families."

ESALY

Eisai

$0.00

(0.00%)

BIIB

Biogen

$226.71

-93.76 (-29.26%)

  • 25

    Mar

  • 24

    Apr

  • 30

    Apr

  • 01

    May

ESALY Eisai
$0.00

(0.00%)

07/06/18
NOMU
07/06/18
UPGRADE
NOMU
Buy
Eisai upgraded to Buy from Neutral at Nomura Instinet
07/10/18
MZHO
07/10/18
NO CHANGE
MZHO
Buy
Biogen, Eisai not sharing details on BAN2401 presentation at AAIC, says Mizuho
After Biogen (BIIB) and partner Eisai's (ESALY) recent announcement that BAN2401 demonstrated statistically significant slowing in clinical decline and reduction of amyloid beta accumulation in a trial of Alzheimer's patients, Mizuho analyst Salim Syed said he has checked with both companies and neither is divulging any details about what sort of data on the trial will be shared at the upcoming AAIC meeting. He maintains a Buy rating and $423 price target on Biogen shares.
08/28/18
PIPR
08/28/18
NO CHANGE
PIPR
Overweight
Piper says Biogen PRIME data has little to change minds of bulls or bears
After Biogen (BIIB) and Eisai (ESALY) announced another year's worth of long term extension data from their ongoing PRIME Phase 1b study of aducanumab, Piper Jaffray analyst Christopher Raymond said he sees little in the release to change the minds of either A-beta bulls or A-beta bears. Raymond, who continues to look toward a full Phase 3 data read-out in early 2020 as the key event for aducanumab, keeps an Overweight rating on Biogen shares.
03/21/19
COWN
03/21/19
NO CHANGE
Target $275
COWN
Outperform
Biogen price target cut to $275 from $400 at Cowen
Cowen analyst Philip Nadeau cut his price target for Biogen (BIIB) to $275 from $400 after the company and its partner Eisai (ESALY) announced that the Phase 3 ENGAGE and EMERGE studies of aducanumab for the treatment of cognitive impairment and dementia in Alzheimer's disease will be stopped for futility. The analyst maintains an Outperform rating.
BIIB Biogen
$226.71

-93.76 (-29.26%)

03/21/19
ADAM
03/21/19
DOWNGRADE
Target $275
ADAM
Hold
Biogen downgraded to Hold from Buy at Canaccord
Canaccord Genuity analyst Sumant Kulkarni downgraded Biogen to Hold from Buy and lowered his price target for the shares to $275 from $396 after the company announced the discontinuation of aducanumab development in mild Alzheimer's disease.
03/21/19
CANT
03/21/19
DOWNGRADE
CANT
Neutral
Biogen downgraded to Neutral from Overweight at Cantor Fitzgerald
03/21/19
STFL
03/21/19
NO CHANGE
STFL
Biogen price target lowered to $233 from $346 at Stifel
Stifel analyst Paul Matteis maintained a Hold rating on Biogen and lowered his price target on shares to $233 from $346 following the drop in the company's stock due to its announcement it would stop its aducanumab phase III studies, ENGAGE and EMERGE, for futility. The analyst said to take a "wait-and-see approach" until there is more visibility in the company's growth and its contingency plan. Matteis noted there are two major catalysts in 2019 -- Novartis Type-2 SMA gene therapy data at AAN, BIIB092 PSP data in the second half of 2019 -- but added that it is hard to get constructive ahead of either event as he worries about the first and lacks conviction in the second.
03/21/19
SBSH
03/21/19
DOWNGRADE
SBSH
Neutral
Biogen downgraded to Neutral from Buy at Citi

TODAY'S FREE FLY STORIES

BAC

Bank of America

$29.57

-0.23 (-0.77%)

, BK

BNY Mellon

$46.38

-0.61 (-1.30%)

09:35
09/23/19
09/23
09:35
09/23/19
09:35
Conference/Events
U.S. Treasury Department to co-host a conference »

The U.S. Treasury Dept,…

BAC

Bank of America

$29.57

-0.23 (-0.77%)

BK

BNY Mellon

$46.38

-0.61 (-1.30%)

BLK

BlackRock

$444.61

0.64 (0.14%)

CS

Credit Suisse

$12.81

-0.05 (-0.39%)

FNMA

Fannie Mae

$0.00

(0.00%)

GS

Goldman Sachs

$213.76

-1.59 (-0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 26

    Sep

  • 15

    Oct

  • 16

    Oct

  • 16

    Oct

  • 27

    Oct

09:35
09/23/19
09/23
09:35
09/23/19
09:35
General news
Breaking General news story  »

New York Federal Reserve…

HUN

Huntsman

$22.49

-0.3 (-1.32%)

09:34
09/23/19
09/23
09:34
09/23/19
09:34
Upgrade
Huntsman rating change  »

Huntsman upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

NFLX

Netflix

$270.66

-15.92 (-5.56%)

09:33
09/23/19
09/23
09:33
09/23/19
09:33
Recommendations
Netflix analyst commentary  »

Release of The Irishman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 16

    Oct

GEL

Genesis Energy

$22.27

-0.43 (-1.89%)

09:32
09/23/19
09/23
09:32
09/23/19
09:32
Hot Stocks
Genesis Energy announces expansion of existing sodium services operations »

Genesis Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:30
09/23/19
09/23
09:30
09/23/19
09:30
General news
PMI Composite FLASH Manufacturing â€' Level to be reported at 09:45 »

September PMI Composite…

09:30
09/23/19
09/23
09:30
09/23/19
09:30
General news
PMI Composite FLASH â€' Level to be reported at 09:45 »

September PMI Composite…

SEV

Sevcon

$0.00

(0.00%)

, XYL

Xylem

$77.61

-0.38 (-0.49%)

09:29
09/23/19
09/23
09:29
09/23/19
09:29
Conference/Events
RBC Capital to hold booth tours and meetings at conference »

RBC Capital Company Booth…

SEV

Sevcon

$0.00

(0.00%)

XYL

Xylem

$77.61

-0.38 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Sep

  • 31

    Oct

MED

Medifast

$108.05

1.52 (1.43%)

09:28
09/23/19
09/23
09:28
09/23/19
09:28
Recommendations
Medifast analyst commentary  »

Medifast CFO confident in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FELE

Franklin Electric

$46.86

-0.66 (-1.39%)

, WTS

Watts Water

$95.13

-0.94 (-0.98%)

09:28
09/23/19
09/23
09:28
09/23/19
09:28
Conference/Events
Seaport Global to hold booth tours at conference »

Seaport Global Company…

FELE

Franklin Electric

$46.86

-0.66 (-1.39%)

WTS

Watts Water

$95.13

-0.94 (-0.98%)

XYL

Xylem

$77.61

-0.38 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

  • 31

    Oct

  • 18

    Nov

FSLR

First Solar

$66.69

-0.4 (-0.60%)

09:27
09/23/19
09/23
09:27
09/23/19
09:27
Hot Stocks
First Solar announces 25GW DC of photovoltaic modules shipped »

First Solar is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:27
09/23/19
09/23
09:27
09/23/19
09:27
Conference/Events
Water Environment Federation to hold a conference »

WEFTEC 2019 will be held…

09:26
09/23/19
09/23
09:26
09/23/19
09:26
Conference/Events
Barclays to hold a forum »

Payments & FinTech…

ADBE

Adobe

$277.84

-3.37 (-1.20%)

, ADP

ADP

$159.15

-0.15 (-0.09%)

09:26
09/23/19
09/23
09:26
09/23/19
09:26
Conference/Events
PagerDuty to hold a summit »

PagerDuty Summit 2019…

ADBE

Adobe

$277.84

-3.37 (-1.20%)

ADP

ADP

$159.15

-0.15 (-0.09%)

AMZN

Amazon.com

$1,793.64

-28.57 (-1.57%)

GOOG

Alphabet

$1,229.57

-10.03 (-0.81%)

IBM

IBM

$141.82

-1.17 (-0.82%)

MSFT

Microsoft

$139.34

-1.74 (-1.23%)

TWLO

Twilio

$114.39

-0.74 (-0.64%)

UBER

Uber

$32.52

-1.31 (-3.87%)

WORK

Slack Technologies

$25.39

-0.375 (-1.46%)

ZEN

Zendesk

$77.73

0.275 (0.36%)

ZM

Zoom Video

$82.68

-1.91 (-2.26%)

PD

PagerDuty

$29.89

0.785 (2.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 23

    Oct

  • 27

    Oct

  • 30

    Oct

  • 13

    Nov

FQVLF

First Quantum Minerals

$0.00

(0.00%)

09:25
09/23/19
09/23
09:25
09/23/19
09:25
Hot Stocks
First Quantum granted right to enter option agreement on Dragonslayer project »

Millrock Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVCY

Central Valley Community

$21.49

0.88 (4.27%)

09:24
09/23/19
09/23
09:24
09/23/19
09:24
Downgrade
Central Valley Community rating change  »

Central Valley Community…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIVE

Five Below

$126.54

-1.89 (-1.47%)

09:23
09/23/19
09/23
09:23
09/23/19
09:23
Recommendations
Five Below analyst commentary  »

Five Below's Ten…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSY

Hershey

$154.15

0.73 (0.48%)

09:22
09/23/19
09/23
09:22
09/23/19
09:22
Hot Stocks
Hershey completes acquisition of ONE Brands for $397M »

The Hershey Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Healthcare

$124.35

-2.51 (-1.98%)

09:20
09/23/19
09/23
09:20
09/23/19
09:20
Hot Stocks
HCA Healthcare CHRO John Steele to retire, Jennifer Berres to succeed »

HCA Healthcare announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

REGN

Regeneron

$295.79

9.51 (3.32%)

, SNY

Sanofi

$46.50

1.61 (3.59%)

09:20
09/23/19
09/23
09:20
09/23/19
09:20
Upgrade
Regeneron, Sanofi, Roche rating change  »

Guggenheim upgrades…

REGN

Regeneron

$295.79

9.51 (3.32%)

SNY

Sanofi

$46.50

1.61 (3.59%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 27

    Sep

  • 02

    Oct

  • 04

    Nov

SVMK

SurveyMonkey

$18.14

-0.16 (-0.87%)

09:20
09/23/19
09/23
09:20
09/23/19
09:20
Hot Stocks
SurveyMonkey achieves ISO recognition from the British Standards Institute »

SurveyMonkey announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$18.46

-0.29 (-1.55%)

09:18
09/23/19
09/23
09:18
09/23/19
09:18
Hot Stocks
HP Inc. partners with WWF on forest protection, restoration, management »

HP announced its next…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
09/23/19
09/23
09:18
09/23/19
09:18
Options
Overnight activity included 303 trades in SPX and 5 trades in VIX »

303 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSCO

Nesco Holdings

$6.75

-0.055 (-0.81%)

09:17
09/23/19
09/23
09:17
09/23/19
09:17
Hot Stocks
Nesco Holdings to acquire Truck Utilities for $42.2M »

Nesco Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BNPQY

BNP Paribas

$0.00

(0.00%)

09:16
09/23/19
09/23
09:16
09/23/19
09:16
Hot Stocks
BNP Paribas becomes founding signatory of Principles for Responsible Banking »

BNP Paribas became one of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.